Pathogen Safety Data Sheets: Infectious Substances – Lassa virus
PATHOGEN SAFETY DATA SHEET - INFECTIOUS SUBSTANCES
SECTION I - INFECTIOUS AGENT
NAME: Lassa virus.
CHARACTERISTICS: Double-segmented, single-stranded RNA virus, belonging to the genus Arenavirus , family Arenaviridae . The viral fragment may occupy several distinct shapes (pleomorphic) measuring 80 to 150nm in diameter(1,4). The surface of the virion lipid envelope is studded with glycoproteins that consist of tetrameric complexes of the viral glycoproteins GP1 and GP2(4).
SECTION II – HAZARD IDENTIFICATION
PATHOGENICITY/TOXICITY: Acute viral illness of 1 to 4 weeks duration(3). Disease may be asymptomatic to mild (80 % of cases), severe, or fatal(1,3,5,6,7). Early symptoms include gradual onset of fever, nausea, abdominal pain, severe sore throat, cough, conjunctivitis, ulceration of buccal mucosa, exudative pharyngitis, and cervical lymphadenopathy(1,3,5,7,8). Late symptoms include severe swelling of head and neck, pleural and pericardial effusions(8,9). Twenty-five percent of cases result in deafness and/or (transient) alopecia(1,3,5,7,10). The disease is severe in pregnancy, resulting in foetal loss in 80 % of cases(3,10). Death as a result of infection with Lassa virus is usually due to cardiac arrest(1). Fatality rate is 15 to 20 % of hospitalized patients and 1 to 2 % of infected individuals in general(1,3,7).
EPIDEMIOLOGY: Endemic in West Africa. Between 10,000 and 300,000 infections occur annually with 5,000 deaths(1,3,6,10). Outbreaks have occurred in Guinea, Liberia (1972), Sierra Leone (1970-72, 1973-75, and 1996-97), areas of Nigeria (first cases in 1969, further outbreaks in 1970, 1974, and 1975), Central African Republic, Democratic Republic of Congo, Mali, Senegal, Benin, Burkina Faso, Cameroon, Ghana, Ivory Coast and Sudan(1,3). Approximately 20 cases of imported Lassa fever have been recorded worldwide(11,12).
INFECTIOUS DOSE: One to 10 aerosolized organisms(13).
MODE OF TRANSMISSION: Transmission from the multimammate rat to humans occurs via aerosols; or by direct contact with rat excretions, or with food and water contaminated with excretions(1,3,6). Infection may occur through cuts and sores or when infected rats are prepared as food(1,4,6). Person-to-person transmission can cause epidemics with a high mortality rate, or be achieved by nosocomial outbreaks involving blood (contaminated needles), pharyngeal secretions and urine or contaminated medical equipment(1,2,3,6,7,15). Lassa virus can also be transmitted via sexual contact or via contact with skin lesions.
COMMUNICABILITY: Person-to-person spread may occur during the acute febrile phase when the virus is present in the throat(3). Lassa virus can be excreted in urine for 3-9 weeks from the onset of illness. Male patients should refrain from unprotected sex until the semen is virus- free for 3 months(2,9).
SECTION III - DISSEMINATION
SECTION IV – STABILITY AND VIABILITY
SUSCEPTIBILITY TO DISINFECTANTS: Lassa virus is susceptible to 0.5 % sodium hypochlorite, phenolic compounds, 3 % acetic acid (pH 2.5), lipid solvents and detergents such as SDS, formaldehyde and paraformaldehyde fixation, formaldehyde fumigation, and β- propiolactone(1,3,4,17,18,19).
PHYSICAL INACTIVATION: Lassa virus can be inactivated by heating serum for 1 hour at 60oC, gamma irradiation (1.2 x106 rads to 1.27 x106 rads), UV irradiation, autoclaving, incineration, and/or boiling(3,4,7,17,19).
SURVIVAL OUTSIDE HOST: The virus is stable as an aerosol, particularly at low relative humidity (30 % RH). The biological half-live at both 24°C and 32°C ranges from 10.1 to 54.6 minutes(20).
SECTION V – FIRST AID / MEDICAL
SURVEILLANCE: Definitive diagnosis is reached mainly upon laboratory testing (i.e. RT-PCR or serological testing) of virus isolation from blood samples, pharyngeal washings, pharyngeal swabs, and/or urine(1,2,3,7).
Note: All diagnostic methods are not necessarily available in all countries.
SECTION VI - LABORATORY HAZARDS
SPECIAL HAZARDS: Work with, or exposure to rodents that are naturally or experimentally infected represents a risk of human infection.
SECTION VII – EXPOSURE CONTROLS / PERSONAL PROTECTION
RISK GROUP CLASSIFICATION: Risk Group 4(22).
CONTAINMENT REQUIREMENTS: Containment Level 4 facilities, equipment, and operational practices for work involving infectious or potentially infectious materials, animals, and cultures.
PROTECTIVE CLOTHING: Personnel entering the laboratory must remove street clothing, including undergarments, and jewellery, and change into dedicated laboratory clothing and shoes, or don full coverage protective clothing (i.e., completely covering all street clothing). Additional protection may be worn over laboratory clothing when infectious materials are directly handled, such as solid-front gowns with tight fitting wrists, gloves, and respiratory protection. Eye protection must be used where there is a known or potential risk of exposure to splashes(23).
OTHER PRECAUTIONS: All activities with infectious material should be conducted in a biological safety cabinet (BSC) in combination with a positive pressure suit, or within a class III BSC line. Centrifugation of infected materials must be carried out in closed containers placed in sealed safety cups, or in rotors that are loaded or unloaded in a biological safety cabinet. The integrity of positive pressure suits must be routinely checked for leaks. The use of needles, syringes, and other sharp objects should be strictly limited. Open wounds, cuts, scratches, and grazes should be covered with waterproof dressings. Additional precautions should be considered with work involving animal activities(23).
SECTION VIII - HANDLING AND STORAGE
SPILLS: Allow aerosols to settle and, wearing protective clothing, gently cover spill with paper towels and apply suitable disinfectant, starting at the perimeter and working towards the centre. Allow sufficient contact time before clean up (30 min)(23).
DISPOSAL: Patient excreta, sputum, blood and all objects with which a patient has had contact with, including laboratory equipment used for testing, should be disinfected with 0.5 % sodium hypochlorite solution or 0.5 % phenol with detergent, followed by autoclaving, incineration or boiling(3). Decontaminate all materials for disposal from the containment laboratory by steam sterilization, chemical disinfection, incineration or by gaseous methods. Contaminated materials include both liquid and solid wastes(23).
STORAGE: In sealed leak-proof containers that are appropriately labelled and locked in a Containment Level 4 laboratory(23).
SECTION IX – REGULATORY AND OTHER INFORMATION
REGULATORY INFORMATION: The import, transport, and use of pathogens in Canada is regulated under many regulatory bodies, including the Public Health Agency of Canada, Health Canada, Canadian Food Inspection Agency, Environment Canada, and Transport Canada. Users are responsible for ensuring they are compliant with all relevant acts, regulations, guidelines, and standards.
UPDATED: September 2010.
PREPARED BY: Pathogen Regulation Directorate, Public Health Agency of Canada.
Although the information, opinions and recommendations contained in this Pathogen Safety Data Sheet are compiled from sources believed to be reliable, we accept no responsibility for the accuracy, sufficiency, or reliability or for any loss or injury resulting from the use of the information. Newly discovered hazards are frequent and this information may not be completely up to date.
Public Health Agency of Canada, 2010
- Acha, P. N., & Szyfres, B. (2003). In Pan American Health Organization (Ed.), Zoonoses and Communicable Diseases Common to Man and Animals (3rd ed.). Washington DC: PAHO HQ library.
- Drosten, C., Go ttig, S., Schilling, S., Asper, M., Panning, M., Schmitz, H., & Gu nther, S. (2002). Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. Journal of Clinical Microbiology, 40 (7), 2323-2330.
- Heymann, D. L. (2008). Control of Communicable Diseases Manual (19th Edition ed.). Washington, D.C.: American Public Health Association.
- Knipe, D. M., & Howley, P. M. (Eds.). (2001). Fields Virology (4th ed.). Philidelphia: Lippincot Williams & Wilkins.
- McCormick, J. B., King, I. J., & Webb, P. A. (1987). A case-control study of the clinical diagnosis and course of Lassa fever. Journal of Infectious Diseases, 155 (3), 445-455.
- McCormick, J. B., Webb, P. A., & Krebs, J. W. (1987). A prospective study of the epidemiology and ecology of Lassa fever. Journal of Infectious Diseases, 155 (3), 437-444.
- Richmond, J. K., & Baglole, D. J. (2003). Lassa fever: Epidemiology, clinical features, and social consequences. British Medical Journal, 327 (7426), 1271-1275.
- Khan, S. H., Goba, A., Chu, M., Roth, C., Healing, T., Marx, A., Fair, J., Guttieri, M. C., Ferro, P., Imes, T., Monagin, C., Garry, R. F., & Bausch, D. G. (2008). New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Research, 78 (1), 103-115.
- Borio, L., Inglesby, T., Peters, C. J., Schmaljohn, A. L., Hughes, J. M., Jahrling, P. B., Ksiazek, T., Johnson, K. M., Meyerhoff, A., O'Toole, T., Ascher, M. S., Bartlett, J., Breman, J. G., Eitzen Jr., E. M., Hamburg, M., Hauer, J., Henderson, D. A., Johnson, R. T., Kwik, G., Layton, M., Lillibridge, S., Nabel, G. J., Osterholm, M. T., Perl, T. M., Russell, P., & Tonat, K. (2002). Hemorrhagic fever viruses as biological weapons: Medical and public health management. Journal of the American Medical Association, 287 (18), 2391- 2405.
- Fisher-Hoch, S. P., Hutwagner, L., Brown, B., & McCormick, J. B. (2000). Effective vaccine for lassa fever. Journal of Virology, 74 (15), 6777-6783.
- Imported Lassa fever - New Jersey, 2004. (2004). Morbidity and Mortality Weekly Report, 53 (38), 894-897.
- Schmitz, H., Ko hler, B., Laue, T., Drosten, C., Veldkamp, P. J., Gu nther, S., Emmerich, P., Geisen, H. P., Fleischer, K., Beersma, M. F. C., & Hoerauf, A. (2002). Monitoring of clinical and laboratory data in two cases of imported Lassa fever. Microbes and Infection, 4(1), 43-50.
- Franz, D. R., Jahrling, P. B., McClain, D. J., Hoover, D. L., Byrne, W. R., Pavlin, J. A., Christopher, G. W., Cieslak, T. J., Friedlander, A. M., & Eitzen E.M., J. (2001). Clinical recognition and management of patients exposed to biological warfare agents. Clinics in Laboratory Medicine, 21 (3), 435-473.
- Heymann, D. L. (Ed.). (2008). Control of Communicable Diseases Manual (19th Edition ed.). Washington, DC: American Public Health Association.
- Update on Lassa fever in West Africa. (2005). Releve Epidemiologique Hebdomadaire / Section d'Hygiene Du Secretariat De La Societe Des Nations = Weekly Epidemiological Record / Health Section of the Secretariat of the League of Nations, 80 (10), 86-88.
- McCormick, J. B., King, I. J., & Webb, P. A. (1986). Lassa fever: Effective therapy with ribavirin. New England Journal of Medicine, 314 (1), 20-26.
- Elliott, L. H., McCormick, J. B., & Johnson, K. M. (1982). Inactivation of Lassa, Marburg, and Ebola viruses by gamma irradiation. Journal of Clinical Microbiology, 16 (4), 704-708.
- Mitchell, S. W., & McCormick, J. B. (1984). Physicochemical inactivation of Lassa, Ebola, and Marburg viruses and effect on clinical laboratory analyses. Journal of Clinical Microbiology, 20 (3), 486-489.
- Mahanty, S., Kalwar, R., & Rollin, P. E. (1999). Cytokine measurement in biological samples after physicochemical treatment for inactivation of biosafety level 4 viral agents. Journal of Medical Virology, 59 (3), 341-345.
- Stephenson, E. H., Larson, E. W., & Dominik, J. W. (1984). Effect of environmental factors on aerosol-induced Lassa virus infection. Journal of Medical Virology, 14 (4), 295-303.
- arboviruses and related zoonotic viruses. (1999). In J. Y. Richmond, & R. W. McKinney (Eds.), Biosafety in Microbiological and Biomedical Laboratories (BMBL) (5th ed., pp. 183- 199). Washington, D.C.: Centers for Disease Control and Prevention.
- Human Pathogens and Toxins Act. S.C. 2009, c. 24. Government of Canada, Second Session, Fortieth Parliament, 57-58 Elizabeth II, 2009, (2009).
- Public Health Agency of Canada. (2004). In Best M., Graham M. L., Leitner R., Ouellette M. and Ugwu K. (Eds.), Laboratory Biosafety Guidelines (3rd ed.). Canada: Public Health Agency of Canada.
Report a problem or mistake on this page
- Date modified: